N/A N=25 Single-blind Diagnostic

Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer

Lung Cancer

Bottom Line

View on ClinicalTrials.gov: NCT02388074 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2015

Primary outcome: Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: CyPath® (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: bioAffinity Technologies Inc.
Primary completion: Apr 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants	—	—

Summary

This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.

Eligibility Criteria

Inclusion Criteria

Participants who have never smoked nor have known lung diseases

Exclusion Criteria

Severe obstructive lung disease
Angina with minimal exertion
Pregnancy
Have or have had cancer other than lung cancer
Worked in the mining Industry

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02388074). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.